

# The wide spectrum biological activities of Piperidine -A short review

**Ramarajan Rajalakshmi**

Department of Chemistry

Annamalai University

Tamil Nadu

India

[chemrajalakshmi@gmail.com](mailto:chemrajalakshmi@gmail.com)


## Abstract

Piperidine is an important heteroatom framework, which demonstrates great function on pharmacological activities, antibacterial, antiviral, antipsychotic, anti-oxidant, anticancer, anti-diabetic, anti-HIV, diuretic activities, neurodegenerative disorders, and so on [1–10]. There are many examples of biologically active piperidine which hold a well-established scientific record as a chemopreventive and therapeutic agent. Herein the polyfunctional piperidine endowed with excellent biological and pharmacological activities are reviewed comprehensively. Compounds containing piperidine structural motif exhibiting therapeutic activities are focussed.

**Key words;** Piperidine, anticancer, anti-diabetic, anti-HIV therapeutic agent

## 1. Introduction

The design and development of highly functionalized piperidine moieties [fig.1] have been continuously growing research interest of chemists due to their unique Physiological and photophysical properties [11]. Several natural products and drugs are found to contain piperidine ring as a structural element and demonstrate high biological activity. Compounds containing piperidine structural motif exhibit anti-hypertensive, anti-bacterial, anti-convulsant, anti-inflammatory, anti-HIV, histamine H3R ligands, antimalarial, antimicrobial and antifungal activities [2-5]. Piperidine possessing Bodipy moieties such as Biodilisan have been reported as the novel fluorescent human histamine H3 receptor ligand. The incorporation of piperidine as bioactive substructure groups into Bodipy platform develops new type of Bodipy dyes illustrating potent photophysical and biological activities [6]. A novel series of multi-receptor ligands have been developed as polypharmacological antipsychotic agents showing a favorable pharmacokinetic profile with oral bioavailability of 58.8% in rats [7]. During a fairly recent 10-year period, several thousand piperidine compounds have been mentioned in clinical and preclinical studies [11]. Besides the interesting structural features, these compounds are also of pharmaceutical interest as they exhibit a wide range of biological activities [12]. Nevertheless, the variety of functionality and substitution patterns found in piperidine targets and the widely accepted concept that the biological properties of piperidines are highly dependent on the type and location of substituents on the heterocyclic ring [13]. Piperidine derivatives are found to possess pharmacological activity and form an essential part of the molecular structures of important drugs such as raloxifene and minoxidil [14]. Selective inhibition of a number of enzymes involved in the binding and processing of glycoproteins has rendered piperidine alkaloids as important tools in the study of biochemical pathways [15]. R. Rajalakshmi et al, reported the synthesis of biologically potent, highly functionalized tetrahydropyridines via one-pot multicomponent reaction using a combination of tetrabutylammonium bromide and iodine as a catalyst for C–N, C–C bond formation [16]. Herein the wide range of biological applications of polyfunctional piperidine are discussed.



[fig.1] Highly functionalized piperidine derivative

### 2.1. Piperidine as Anti-cancer agent

The uncontrolled division of cells results in the formation of tumour having the potential to migrate from one part to the other parts of the body (metastasis) that become a major threat to human beings. Since piperidine exhibits great potential in this area it is being further probed to get novel entities for the treatment of cancer. This review aims to throw light on recent pharmacological and biological expansions of piperidine derivatives along with structure activity relationships to deliver association between various synthesized newer/novel derivatives and receptor sites.

A series of 2-amino-4-(1-piperidine) pyridine derivatives that adopted a novel conformation binding to kinase domain of ALK have designed and synthesized by Siming Liu *et al*[17]., Biological evaluation of most of these new compounds could also potently inhibit ROS1 enzyme, leading to the promising inhibitors against both ROS1 and ALK. These compounds also exhibit moderate to high inhibitory activity in cellular anti-proliferation assay.

Prasad *et al*[18] synthesised an array of diphenyl(Piperidine-4-yl)methanol derivatives. These were evaluated for their antiproliferative action by MTT assay against HT-29, eLa, MCF-7 and HepG2 cell lines. When all the derivatives were tested against the fore mentioned cell lines, compound **displayed** superior inhibitory action against all the cell lines .

Vashishtha *et al* [19] synthesised a variety of aryloxyaryl Mannich bases containing piperidine ring and screened for their anticancer agents activities against seven colon cancer cell lines the data were compared to standard drug melphalan and 5-FU. The results of their activity against seven cell lines of colon cancer revealed that compounds displayed highest activity against HCT116 (IC<sub>50</sub> =3.80 μM) and KM12 (IC<sub>50</sub> =2.57 μM) cell lines. When activity was measured against COLO205, HT29 & HCT-15; compound was most potent of all the synthesised mannich bases with IC<sub>50</sub> values of 12 μM, 3.31 μM and 3.98 μM, respectively. Similar was the case with compound when tested against SW-620 (IC<sub>50</sub> =6.61 μM) & HCC-2998 (IC<sub>50</sub> =12.0 μM) cell lines. Structure activity relationship revealed that Oxygen atom as a linker is essential for cytotoxic action. Replacement of oxygen by Sulphur increases the cytotoxic potential. There is an enhancement in the activity when an electron withdrawing groups (R) is substituted.

A series of 3,5-bis(arylidene)-4-piperidone (DAP) were prepared as curcumin analogue and evaluated [20] for its cytotoxic properties. The anticancer activity of these compounds against H9c2 MCF-7 noncancerous cell lines and A2780 cancer cell line were evaluated. They demonstrated good damages to cell viability in tumour cell line with minimum toxicity to noncancerous cells.

Vinaya *et al* [21] synthesised 4-[3-(piperidin-4-yl)propyl]piperidin-1-ylmethanone derivatives for further examination of piperidine moiety. Upon evaluation of antiproliferative action; compound **57** (IC<sub>50</sub> for K562 = 2.0 ± 1.3 μM; for Reh = 2.3 ± 1.5) effectively inhibits the proliferation of human leukemia cell lines- K562 and Reh by induction of apoptosis. Structure activity relation stated that presence of electron withdrawing groups is essential for potential antiproliferative activity.

Paweł. Niedziałkowski *et al* [22], have synthesized a series of novel 9, 10-anthraquinone derivatives containing piperidine. The antiproliferative activities of the studied compounds were evaluated *in vitro* using drug-sensitive and drug-resistant human cancer cell lines. The conducted test results show that the compound 1 containing a piperidine moiety in their structure is found to be the most active drug among all the molecules subjected to analysis.

Some new hydroxamate derivatives with alkylpiperidine and alkylpiperazine linker moieties have been designed[24], synthesized and biologically evaluated. All these compounds are effective HDAC8 inhibitors comprising more or less similar cytotoxic potential against different cancer cell lines. It is observed that the piperazine scaffold containing compound is more active than the compound with piperidine scaffold for exerting HDAC8 inhibitory activity. Moreover, the 4-quinolyl cap group is better than the biphenyl group which is better than the benzyl group for producing higher HDAC8 inhibition as well as cytotoxicity. These compounds displayed selective HDAC8 inhibition over HDAC3. Moreover, these compounds showed an increased caspase3/7 activity suggesting their anticancer potential through modulation of apoptotic pathways. Molecular docking study with three potent compounds was performed with both HDAC3 and HDAC8 enzymes to understand the selectivity profile of these compounds. Compound containing 4-quinolyl cap group with alkyl piperazinyl urea linker moiety has been emerged out as the lead molecule that may be further modified to design more effective and selective HDAC8 inhibitors in future.

## 2.2. Piperidine as Anti-diabetic agent

Siva Prasad Kasturi *et al* [24], have synthesized novel 3, 4-dihydropiperidine compounds and evaluated their  $\alpha$ -glucosidase inhibitory activity. All the compounds have shown excellent activity. Polar substituents on phenyl ring improve the potency of the compounds.

Diabetes is a life long disorder and needs long-term medical treatment extensive studies to explore more effective and safe drugs are essential. In this therapeutic field, chemists have reported recently the first biological evaluation of aza-flavanones[25] and natural product inspired scaffolds of piperidine as potent inhibitors of  $\alpha$ -glucosidase [26].

It is known that compounds containing the piperidine heterocycle have crucial biological and pharmacological properties such as anaplastic, tyrosinase, proteasome, lymphoma kinase (ALK), Poly (ADP-ribose) polymerase (PARP), aromatase, telomerase, topoisomerase, carbonic anhydrase inhibitors[27-35]. So, synthetic organic chemist aimed to bind the piperidine groups to their targeted organic compounds to increase the biological and pharmacological properties of the planned organic compounds

## 2.3As Potential Multireceptor Antipsychotics

The atypical antipsychotics (AAP; also known as second generation antipsychotics (SGAs)) are a group of antipsychotic drugs (antipsychotic drugs in general are also known as major tranquilizers and neuroleptics, although the latter is usually reserved for the *typical antipsychotics*) largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval. Atypical antipsychotics are typically used to treat schizophrenia or bipolar disorder[36-40]. They are also frequently used to treat agitation associated with dementia, anxiety disorder, autism spectrum disorder, and obsessive-compulsive disorder (an off-label use)[41]. Therefore this review focused on the recent developments in drugs incorporated with piperidine nucleus possessing antipsychotic activity.

The discovery and optimization of novel acetylcholine-binding protein ligands through screening, structure-activity relationships and structure-based design was reported by Jian shen *et al*[42]. They manually screened in-house CNS-biased compound library *in vitro* and identified compound 1, a piperidine derivative, as an initial hit with moderate binding affinity against AChBP (17.2% inhibition at 100 nmol/L). The results suggested that a different piperidinyl substitution might confer a better fit for epibatidine as the reference compound. Thus, compound 15 was designed and identified as a highly affinitive acetylcholine-binding protein ligand. In this study, through two rounds of optimization, compound 15 ( $K_i=2.8$  nmol/L) has been identified as a novel, piperidine-based acetylcholine-binding protein ligand with a high affinity.

A novel series of multireceptor ligands incorporated with piperidine nucleus was developed [43] as polypharmacological antipsychotic agents using the designed multiple ligand approach between dopamine receptors and serotonin receptors[42]. They possess unique pharmacological features, exhibiting high affinities for D<sub>2</sub>, D<sub>3</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>6</sub> receptors and low efficacy at the off-target receptors (5-HT<sub>2C</sub>, histamine H<sub>1</sub>, and adrenergic  $\alpha_1$  receptor). Showing dose-dependent inhibition of apomorphine- and MK-801-induced motor behavior, and the conditioned avoidance response with low cataleptic effect. Moreover, Additionally, these compounds exhibit a favorable pharmacokinetic profile with oral bioavailability of 58.8% in rats. Furthermore, these compounds display procognition properties in a novel object recognition task in rats. Taken

together,

A series of novel benzoxazole-piperidine (piperazine) derivatives combining high dopamine D2 and serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub> receptor affinities were developed[44]. Of these derivatives, the pharmacological features of these compound exhibited high affinities for the DA D<sub>2</sub>, 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors, but low affinities for the 5-HT<sub>2C</sub> and histamine H<sub>1</sub> receptors and human ether-a-go-go-related gene (hERG) channels. Furthermore, benzoxazole-piperidine reduced apomorphine-induced climbing and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced head twitching without observable catalepsy, even at the highest dose tested. Thus, benzoxazole-piperidine is a promising candidate as a multi-target antipsychotic treatment.

A new diaryl-methylene piperidine derivative, [45], displayed an atypical antipsychotic profile both in vitro and in vivo. The main pharmacological characteristics of this compound appears to reside in a more potent antagonism of the 5-HT<sub>2</sub> serotonergic receptor than of the D<sub>2</sub> dopaminergic receptor. This confirms that molecules displaying a D<sub>2</sub>/5-HT<sub>2</sub> binding ratio < 1 possess clozapine-like antipsychotic activity.

. A series of 2-substituted-5-thiopropylpiperazine (piperidine) -1,3,4-oxadiazoles derivatives have been synthesized[46] and the target compounds were evaluated for binding affinities to D(2), 5-HT(1A) and 5-HT(2A) receptors. Preliminary results indicated that compounds 14, 16 and 22 exhibited high affinities to D(2), 5-HT(1A) and 5-HT(2A) receptors among these compounds. Further binding tests showed that compound 22 had high affinity for D(3) receptor, and low affinity for serotonin 5-HT(2C) and H(1) receptors. In addition, compound 22 inhibited apomorphine-induced climbing behavior and MK-801-induced hyperactivity with no extrapyramidal symptoms liability in mice. They have shown an atypical antipsychotic activity without liability for extrapyramidal symptoms.

#### 2.4. As HIV-1 Inhibitors

A novel series of piperidine-substituted triazine derivatives[47] have been synthesized and evaluated for anti HIV activities in MT-4 cells. Most compounds displayed extremely promising activity against wild-type HIV-1 with EC<sub>50</sub> values in low nanomolar concentration, better than that of Nevirapine, Delaviridine and Dideoxycytidine, and higher potency towards the resistant mutant strain K103N/Y181C than that of Nevirapine and Delaviridine. Selected compounds were also assayed against reverse transcriptase with lower IC<sub>50</sub> values than that of Nevirapine.

[  
A series of novel N-arylmethyl substituted piperidine-linked aniline derivatives were designed, synthesized and evaluated for their anti-HIV activity in MT-4 cell [48]s. All the new compounds showed moderate to potent activities against wild-type (wt) HIV-1 with an EC<sub>50</sub> range from 0.022 to 2.1 μM. All the compounds (EC<sub>50</sub>=0.022±0.0091 μM, SI >10,770) were confirmed to be the most potent and selective inhibitor, which proved more potent than DDI and DLV in a cell-based assay against wt HIV-1, and more efficient than NVP in an RT (reverse transcriptase) assay.

A novel series of 1-acetylpiperidin-4-yl group led were synthesized and reported as potent CCR5 antagonists [49]. Introduction of small hydrophobic substituents on the central phenyl ring increased the binding affinity, providing low to sub-nanomolar CCR5 antagonists. The selected compound 11f showed excellent antiviral activity against CCR5-using HIV-1 replication in human peripheral blood mononuclear cells (EC<sub>50</sub>=0.59 nM) and an acceptable pharmacokinetic profile in dogs

A series of N<sub>2</sub>-(1-(substituted-aryl) piperidin-4-yl)-N<sub>6</sub>-mesityl-9H-purine-2,6-diamine derivatives were synthesized and proved as potent antiviral agents. Preliminary biological evaluation indicated that nearly half of them possessed remarkable HIV inhibitory potencies in cellular assays [50]. In particular, FZJ13 appeared to be the most notable one, which displayed anti-HIV-1 activity compared to 3TC. Moreover, an unexpected finding was that FZJ05 displayed significant potency against influenza A/H1N1 (strain A/PR/8/34) in MDCK cells with EC<sub>50</sub> values much lower than those of ribavirin, amantadine and

rimantadine. The results suggest that these novel purine derivatives incorporated with piperidine nucleus have the potential to be further developed as new therapeutic agents against HIV-1 or influenza virus.

A series of novel piperidine-substituted thiophene[3,2-*d*]pyrimidine derivatives[51] were designed to explore the hydrophobic channel of the non-nucleoside reverse transcriptase inhibitors binding pocket (NNIBP) by incorporating an aromatic moiety to the left wing of the lead **K-5a2**. The newly synthesized compounds were evaluated for anti-HIV potency in MT-4 cells and inhibitory activity to HIV-1 reverse transcriptase (RT). Most of the synthesized compounds exhibited broad-spectrum activity toward wild-type and a wide range of HIV-1 strains carrying single non-nucleoside reverse transcriptase inhibitors (NNRTI)-resistant mutations.

### 2.5.As Anti-inflammatory agent

4,5-disubstituted-thiazolyl amides, derivatives of 4-hydroxy-piperidine and of 4-N-methyl piperazine, were synthesized and tested as anti-inflammatory agents[52]. Log P values were theoretically calculated and experimentally determined. These compounds were tested for antioxidant activity, as hydroxyl radical scavengers and for their ability to interact with stable 1, 1-diphenyl-2-picryl hydrazyl free radical (DPPH). The effect of the synthesized compounds on inflammation, using the carrageenin induced mice paw edema model was studied. Both anti-inflammatory and antioxidant activities depended on some structural characteristics of the synthesized compounds.

The synthesis and pharmacological evaluation of novel carboxamide and thioamide derivatives from the benzophenone and piperidine nucleus was reported by K.vinaya et al.,[53] Variation in the functional group at the N-terminal of piperidine led to two sets of compounds, bearing the carboxamide and thioamide, respectively. The characterization of this new class of compounds was performed with (1)H-NMR, LC-MS, IR, and elemental analysis. The newly synthesized compounds were screened for their anti-inflammatory activity by carrageenan-induced foot pad oedema assay and were compared with a standard drug. All the compounds exhibited anti-inflammatory activity at the dose of 30 mg/kg p.o. with varying degree from 52 to 67% inhibition of oedema. The compounds with dichloro and fluoro substitution showed more potent activity at 30 mg/kg p.o. than the standard drug.

A new series of 5-(1-adamantyl)-4-arylideneamino-3-mercapto-1,2,4-triazoles, the *N*-Mannich bases 5-(1-adamantyl)-4-arylideneamino-2-(4-substituted-1-piperazinylmethyl)-1,2,4-triazoline-3-thiones and 5-(1-adamantyl)-4-arylideneamino-2-(4-ethoxycarbonyl-1-piperidyl-methyl)-1,2,4-triazoline-3-thiones were synthesized and their antimicrobial and anti-inflammatory activity was determined[54]. Several of the newly synthesized derivatives displayed promising antimicrobial and anti-inflammatory activities compared to known antibacterial, antifungal and anti-inflammatory drugs.

Antioxidant and anti-inflammatory activity of 1, 3-dimethyl 2, 6-diphenyl piperidine 4-one oxime were investigated. Results of the study indicates that higher dose of 3, 3-dimethyl 2, 6-dimethyl piperidine 4-one oxime has potent anti-inflammatory activity close to standard drug [55]. The antioxidant activity of 3, 3- dimethyl 2,6-dimethyl piperidine 4-one oxime was concentration dependent and approximately comparable to commercial synthetic antioxidants as ascorbic acid. Anti-inflammatory activity was evaluated using the carrageenan induced rat paw oedema. On the basis of the results, it is clearly indicated that 3, 3- dimethyl 2,6-dimethyl piperidine 4-one oxime had powerful anti-inflammatory and in vitro antioxidant activity.

A series of some novel 2,4-dimethoxy-6-(piperazin-1-yl)-1,3,5-triazine aryl ureido/aryl amido derivatives of biological interest were prepared and screened for their pro-inflammatory cytokines (TNF- $\alpha$  and IL-6) and antimicrobial activity. All the compounds were found to have promising anti-inflammatory activity [56]

## Conclusion

This review brought out piperidine containing heterocyclic compounds as a privileged molecule in the field of pharmaceutical sciences with its broad spectrum biological profile including various targets to explore huge scientific knowledge for designing and development of newer/novel piperidine analogs. The thorough knowledge of structure activity relationship will definitely help the scientific community to produce potent drugs with enhanced pharmacological activity.

## References

- [1] P. Martins, J. Jesus, S. Santos, L.R. Raposo, C. Roma-Rodrigues, P.V. Baptista, A.R. Fernandes, Tool Box. *Molecules* 20 (2015) 16852-16891.
- [2] M. Bajda, K.J. Kuder, D. Lazewska, K. Kiec-Kononowicz, A. Wieckowska, M. Ignasik, N. Guzior, J. Jonczyk, B. Malawska, *Arch. Pharm. Chem. Life. Sci.* 345 (2012) 591-597.
- [3] M. Pivatto, L.R. Baccini, A. Sharma, M. Nakabashi, A. Danuello, C.J. Viegas, C.R.S. Garcia, V.S. Bolzani, J. Braz, *Chem. Soc.* 25 (2014) 1900–1906.
- [4] A.P. Rajput, D.V. Nagarale, *Pharm. Chem.* 8 (2016) 182-186.
- [5] F.Y. Li, Y.J. Zhu, Z.J. Fan, J.H. Xu, X.F. Guo, G.N. Zong, H.B. Song, L. Chen, Y.Q. Song, X.L. Qian, *Chin. J. Struct. Chem.* 34 (2015) 659–666.
- [6] M. Tomasch, J.S. Schwed, A. Paulke, H. Stark, *Med. Chem. Lett.* 4 (2013) 269-273
- [7] Guisen Zhang *et al.*, *J. Med. Chem.*, 2018
- [8] Esra Tanrıverdi Eçik *et al.*, *glumin.2018.09.024*
- [9] K. Kumaravel and G. Vasuki, *Curr. Org. Chem.*, 2009, 13, 1820–1841.
- [10] E. R. Bonfield and C. J. Li, *Adv. Synth. Catal.* 2008, 350, 370–374.
- [11] Watson PS, Jiang B, Scott B. *Org. Lett.* 2000; 2: 3679–3681.
- [12] Schneider MJ. *Chemical and Biological*, 1996, Vol. 10, pp 155–299.
- [13] Risi CD, *et al.*, *Tet. Asymn.* 2008; 19:131-155..
- [14] Gulluoglu MT, *et al.* *Mol. Struct.* 2007; 834–836: 540–547.
- [15] Asano N, Nash RJ, Molyneux RJ, Fleet GW. *J. Tet. Asymn.* 2000; 11: 1645.
- [16] Weintraub MP, *et al.*, *Tetr.* 2003; 59: 2953–2989.
- [17]. Siming Liu *et al* *European Journal of Medicinal Chemistry* 179 358e375 (2019)
- [18] Prasad SB, *et al.*, *Medicinal chemistry research.* 2010 (19) 220-235.
- [19] Vashishtha *et al* *European journal of medicinal chemistry.* 2004 (39) 27-35.
- [20] Kálai T, *et al.*, *Journal of medicinal chemistry.* 2011 (54) 5414-5421
- [21] Vinaya *et al* *Chemical biology & drug design.* 2011 (78) 622-630.
- [22] Paweł. Niedziakowski *et a Journal of Molecular Structure* (2018), doi: 10.1016/j.molstruc.2018.07.070.
- [23] Prakrudi Trivedi *European Journal of Pharmaceutical Sciences* Volume 138, 1 October 2019, 105046
- [24] S. Kasturi, S. Surarapu, C.C. Bathoju, S. Uppalanchi, S. Dwivedi, Y. Perumal, D.K. Sigalapalli, B.N. Babu, K.S. Ethiraj, J.S. Anireddy, *Med. Chem. Comm.* 8 (2017) 1618-1630.
- [25] S. Kasturi *et al.*, *Bioorg. Med. Chem. Lett.* 27 (2017) 2818-2823.
- [26] S.P. Kasturi, *et al.*, *European Journal of Medicinal Chemistry* (2018), 02.072
- [27] S. Ferro, L. De Luca, M.P. German, M.R. Buemi, L. Ielo, G. Certo, M. Kanteev, A. Fishman, A. Rapisarda, R. Gitto, *Eur. J. Med. Chem.* 125 (2017) 992-1001.
- [28] P. Wang, J. Cai, J. Chen, M. Ji, *ur. J. Med. Chem.* 93 (2015) 1-8.
- [29] R. Zhuang, L. Gao, X. Lv, J. Xi, L. Sheng, Y. Zhao, R. He, X. Hu, Y. Shao, X. Pan, [29] [30] S. Liu, *Eur. J. Med. Chem.* 126 (2017) 1056-1070.
- [31] H. Li, Y. Hu, X. Wang, G. He, Y. Xu, Q. Zhu, *Bioorg. Med. Chem.* 24 (2016) 4731-4740.
- [32] M. Di Matteo *et al.*, *Bioorg. Med. Chem. Lett.* 26 (2016) 3192-3194.
- [33] X.H. Liu *et al.*, *Eur. J. Med. Chem.* 51 (2012) 294-299
- [34] K. Pors *et al.*, *J. Med. Chem.* 49 (2006) 7013-7023.
- [35] H. Turkme *et al.*, *Bioorg. Med. Chem. Lett.* 15 (2005) 367-372.
- [36] Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (January 2009). " *Lancet.* 373 (9657): 31–41.
- [37] S, Cipriani A, Spinelli L, Mavridis D, Orey D, Richter F, *et al.* (September 2013). " *Lancet.* 382 (9896): 951–62.

- [38]^ "A roadmap to key pharmacologic principles in using antipsychotics". *Primary Care Companion to the Journal of Clinical Psychiatry*. 9 (6): 444–54. 2007. .
- [39]^ Tyrer P, Kendall T (January 2009). *Lancet*. 373 (9657)4–5.
- [40]"Respiridone". *The American Society of Health-System Pharmacists*. Retrieved April 3, 2011.
- [41]^ Maher AR, Maglione M, Bagley S, Suttrop M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG (September 2011). "JAMA". 306 (12)
- [42]Jian shen et al *Acta Pharmacologica Sinica* volume 38, pages146–155(2017)
- [43]Xudong cao et al *J. Med. Chem.* 2018, 61, 22, 10017-10039
- [44]Huang L0Bioorg Med Chem Lett. 2015 Nov 15; 25(22):5299-305.
- [45]Talaga P Bioorg Med Chem Lett. 2001 May 21; 11(10):1313-6
- [46]Yin chen et al.,plos one 7(4):35186 2012
- [47]Xuwang chen *European Journal of Medicinal Chemistry*Volume 51, May 2012, Pages 60-66
- [48]Xuwang chen et al., *Bio organic and Med.Chem* 22(1) November 2013
- [49]S.Imamura et al.,*Bio organic and Med.Chem*2005 Jan 17; 13(2):397-416
- [50]Kang dongwei et al.,*Chemical Biology & Drug Design* 86(4) · January 2015
- [51]Kang dongwei et al.,*Acta Pharmaceutica Sinica B*2019
- [52]A.Geronikaki et al., *Molecules* 2003, 8(6), 472-479;
- [53]K.vinaya et al.,*Arch Pharm (Weinheim)*. 2009 Aug; 342(8):476-83
- [54]Mohamad A.Al.Omerr et al.,*Molucules*. 2010 Apr; 15(4): 2526–2550
- [56]K. Tharani and P. Sangeetha *Int. J. Chem. Sci.*: 13(4), 2015, 1794-1804
- [56]S.Ravindra et al.,*Journal of organic and pharmaceutical research* 2020